RT @UNCneurosurgery: A unique vaccine trial for newly diagnosed #GBM patients opens on 10/25 @UNC_Health_Care – the only site in NC to offe…

A unique vaccine trial for newly diagnosed #GBM patients opens on 10/25 @UNC_Health_Care – the only site in NC to offer this trial: https://t.co/SWOfSUUgGX @yasmeenrauf @UNC_SOM https://t.co/ohuBfZsjOy

Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma https://t.co/prmvRfYZii

Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma https://t.co/aaiDhV420B

RT @KimmelCancerCtr: In a phase 1b #clinicaltrial led by Jefferson Drs. David Andrews & Craig Hooper, IGV-001, a new tumor cell #vaccine, s…

Exciting new research in the treatment of #gliobastoma!

RT @KimmelCancerCtr: In a phase 1b #clinicaltrial led by Jefferson Drs. David Andrews & Craig Hooper, IGV-001, a new tumor cell #vaccine, s…

In a phase 1b #clinicaltrial led by Jefferson Drs. David Andrews & Craig Hooper, IGV-001, a new tumor cell #vaccine, showed promising results in patients with newly diagnosed #glioblastoma, an aggressive #braintumor: https://t.co/Qk8Y1tloBA @CCR_AACR @

RT @NatRevClinOncol: In a phase I trial of implantation of autologous glioblastoma cells following ex vivo treatment with an antisense olig…

In a phase I trial of implantation of autologous glioblastoma cells following ex vivo treatment with an antisense oligonucleotide against IGF-1R (IMV-001) & irradiation, mPFS was 9.8 months which compares favourably with historical outcomes: https://t.

IGV-001, which combines autologous #glioblastoma #tumorcells and antisense oligonucleotide against insulin-like growth factor type 1 receptor, is well tolerated with improved progression free survival in newly diagnosed glioblastoma. https://t.co/u4sDVJvk

Clinical Trial of IGV-001 for Patients with Newly Diagnosed #Glioblastoma. https://t.co/fj0Zu9rJbV

Phase 1b Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma https://t.co/if8ZJpKjaE